View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
May 4, 2011

Lymphoseek Detects Lymph Nodes

Neoprobe has announced results from its Lymphoseek (tilmanocept) NEO3-09 study. The Phase III clinical study enrolled 150 subjects with either breast cancer or melanoma within the intent-to-treat (ITT) population, and showed that Lymphoseek significantly detected all lymph nodes.

By cms admin

Neoprobe has announced results from its Lymphoseek (tilmanocept) NEO3-09 study.

The Phase III clinical study enrolled 150 subjects with either breast cancer or melanoma within the intent-to-treat (ITT) population, and showed that Lymphoseek significantly detected all lymph nodes.

The NEO3-09 study highlighted Lymphoseek’s superior performance in intraoperative lymphatic mapping, a procedure in which lymph nodes are identified for biopsy to assess for the presence of tumour, compared to the use of vital blue dye.

Lymphoseek met all primary and secondary endpoints of the NEO3-09 study.

Dr Vernon Sondak, chief of the oncology division at H Lee Moffitt Cancer Center and Research Institute, said Lymphoseek provided clinically meaningful advantages over blue dyes, and was found to be safe and well-tolerated.

Lymphoseek also exhibited superior performance in detecting lymph nodes containing cancer.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management